Novartis Weighted Average Shares Trend from 2010 to 2020

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

Novartis Weighted Average Shares yearly trend continues to be relatively stable with very little volatility. Weighted Average Shares is likely to grow to about 2.6 B this year. During the period from 2010 to 2020, Novartis Weighted Average Shares destribution of quarterly values had r-value of  0.43 from its regression line and mean deviation of  61,514,621. Novartis Research and Development Expense is relatively stable at the moment as compared to the past year. Novartis reported last year Research and Development Expense of 9.4 Billion. As of 07/11/2020, Weighted Average Shares is likely to grow to about 2.6 B, while Gross Profit is likely to drop slightly above 32.6 B.

Search Historical Trends

 
Refresh
Check Novartis financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Consolidated Income of 12.1 B, Cost of Revenue of 14.2 B or Earning Before Interest and Taxes EBIT of 14.8 B, as well as many exotic indicators such as Asset Turnover of 0.37, Book Value per Share of 29.65 or Current Ratio of 1.05. This can be a perfect complement to check Novartis Valuation or Volatility. It can also complement various Novartis Technical models. Additionally, see the analysis of Novartis Correlation with competitors.

Novartis Weighted Average Shares Marginal Breakdown

Showing smoothed Weighted Average Shares of Novartis AG with missing and latest data points interpolated. The weighted average number of shares or units issued and outstanding that are used by the company to calculate [EPS]; determined based on the timing of issuance of shares or units in the period.
ViewLast Reported 2.29 B10 Years Trend
Increasing
Slightly volatile
 Weighted Average Shares 
      Timeline 

Novartis Weighted Average Shares Regression Statistics

Arithmetic Mean 2,378,201,699
Geometric Mean 2,376,815,573
Coefficient Of Variation 3.61
Mean Deviation 61,514,621
Median 2,374,059,013
Standard Deviation 85,971,683
Range 312,461,474
R-Value 0.43
R-Squared 0.19
Significance 0.18
Slope 11,238,077

Novartis Weighted Average Shares Over Time

20102.3 B
20112.3 B
20122.4 B
20132.4 B
20142.4 B
20152.4 B
20162.4 B
20172.4 B
20182.3 B
20192.3 B
20202.6 B

About Novartis Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's Weighted Average Shares, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Current Assets28.21 B35.56 B29.5 B32.46 B
Total Assets133.08 B145.56 B118.37 B134.45 B

Current Sentiment - NVS

Novartis AG Investor Sentiment

Predominant part of Macroaxis users are now bullish on Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Novartis Correlation with competitors. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page